Nras in melanoma: Targeting the undruggable target

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 2, 2014, Pages 107-122

  Mandalà, Mario ^a   Merelli, Barbara ^a   Massi, Daniela ^b  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Melanoma; NRAS; Predictive; Prognostic; Resistance

Indexed keywords

NEUROBLASTOMA RAS PROTEIN; RAS PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

APOPTOSIS; CANCER CELL; CANCER PROGNOSIS; CANCER RESISTANCE; CELL METABOLISM; CELL PROLIFERATION; DRUG TARGETING; HUMAN; MELANOMA; METASTASIS; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION;

ANTINEOPLASTIC AGENTS; GTP PHOSPHOHYDROLASES; HUMANS; MELANOMA; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION;

EID: 84908354341     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.05.005     Document Type: Review

References (104)

1. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465.
2. Chang E.H., Furth M.E., Scolnick E.M., Lowy D.R. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 1982, 297:479-483.
3. Chang E.H., Gonda M.A., Ellis R.W., Scolnick E.M., Lowy D.R. Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A 1982, 79:4848-4852.
4. Der C.J., Krontiris T.G., Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A 1982, 79:3637-3640.
5. Parada L.F., Tabin C.J., Shih C., Weinberg R.A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982, 297:474-478.
6. Shimizu K., Goldfarb M., Suard Y., et al. Three human transforming genes are related to the viral ras oncogenes. Proc Natl Acad Sci U S A 1983, 80:2112-2116.
7. Henis Y.I., Hancock J.F., Prior I.A. Ras acylation, compartmentalization and signaling nanoclusters. Mol Membr Biol 2009, 26:80-92. [Review].
8. Mor A., Philips M.R. Compartmentalized Ras/MAPK signaling. Annu Rev Immunol 2006, 24:771-800.
9. Moodie S.A., Willumsen B.M., Weber M.J., Wolfman A. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993, 260:1658-1661.
10. Vojtek A.B., Hollenberg S.M., Cooper J.A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 1993, 74:205-214.
11. Warne P.H., Viciana P.R., Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 1993, 364:352-355.
12. Zhang X.F., Settleman J., Kyriakis J.M., et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 1993, 364:308-313.
13. Seger R., Krebs E.G. The MAPK signaling cascade. FASEB J 1995, 9:726-735.
14. Rodriguez-Viciana P., Warne P.H., Dhand R., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532.
15. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
16. Mandalà M., Voit C. Targeting BRAF in melanoma: biological and clinical challenges. Crit Rev Oncol Hematol 2013, 87:239-255.
17. Feramisco J.R., Gross M., Kamata T., Rosenberg M., Sweet R.W. Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell 1984, 38:109-117.
18. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
19. Finco T.S., Westwick J.K., Norris J.L., Beg A.A., Der C.J., Baldwin A.S. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 1997, 272:24113-24116.
20. Westwick J.K., Cox A.D., Der C.J., et al. Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases. Proc Natl Acad Sci U S A 1994, 91:6030-6034.
21. Winston J.T., Coats S.R., Wang Y.Z., Pledger W.J. Regulation of the cell cycle machinery by oncogenic ras. Oncogene 1996, 12:127-134.
22. Chin L., Tam A., Pomerantz J., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
23. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005, 102:8573-8578.
24. Semenza G.L. Hypoxia and cancer. Cancer Metastasis Rev 2007, 26:223-224.
25. Chiaradonna F., Sacco E., Manzoni R., Giorgio M., Vanoni M., Alberghina L. Ras-dependent carbon metabolism and transformation in mouse fibroblasts. Oncogene 2006, 25:5391-5404.
26. Kranenburg O., Gebbink M.F., Voest E.E. Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta 2004, 1654:23-37.
27. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716.
28. Ancrile B.B., O'Hayer K.M., Counter C.M. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol Interv 2008, 8:22-27.
29. Blasi F., Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3:932-943.
30. Seliger B., Harders C., Wollscheid U., Staege M.S., Reske-Kunz A.B., Huber C. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp Hematol 1996, 24:1275-1279.
31. Kubuschok B., Neumann F., Breit R., et al. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 2006, 12:1365-1372.
32. Tran Thang N.N., Derouazi M., Philippin G., et al. Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res 2010, 70:4829-4839.
33. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994, 124:619-626.
34. Campbell P.M., Der C.J. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 2004, 14:105-114.
35. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005, 386:193-205.
36. Chin L., Garraway L.A., Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006, 20:2149-2182.
37. Whitwam T., Vanbrocklin M.W., Russo M.E., et al. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene 2007, 26:4563-4570.
38. Prior I.A., Hancock J.F. Compartmentalization of Ras proteins. J Cell Sci 2001, 114(Pt 9):1603-1608.
39. Ross A.L., Sanchez M.I., Grichnik J.M. Molecular nevogenesis. Dermatol Res Pract 2011, 2011:463184.
40. Ichii-Nakato N., Takata M., Takayanagi S., et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol 2006, 126:2111-2118.
41. Dessars B., De Raeve L.E., Morandini R., et al. Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. J Invest Dermatol 2009, 129:139-147.
42. Charbel C., Fontaine R.H., Malouf G.G., et al. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol 2013, (October).
43. Ichii-Nakato N1, Takata M., Takayanagi S., et al. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol 2006, 126:2111-2118.
44. Bauer J., Curtin J.A., Pinkel D., Bastian B.C. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007, 127:179-182.
45. Phadke P.A., Rakheja D., Le L.P., et al. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. Am J Surg Pathol 2011, 35:656-669.
46. Pedersen M., Küsters-Vandevelde H.V., Viros A., et al. Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov 2013, 3:458-469.
47. Gessi M., Hammes J., Lauriola L., et al. GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system. Neuropathol Appl Neurobiol 2013, 39:417-425.
48. Kinsler V.A., Thomas A.C., Ishida M., et al. Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 2013, 133:2229-2236.
49. Carr J., Mackie R.M. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994, 131:72-77.
50. Jafari M., Papp T., Kirchner S., et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol 1995, 121:23-30.
51. Albino A.P., Nanus D.M., Mentle I.R., et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989, 4:1363-1374.
52. Eskandarpour M., Hashemi J., Kanter L., Ringborg U., Platz A., Hansson J. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst 2003, 95:790-798.
53. Tschandl P., Berghoff A.S., Preusser M., et al. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLOS ONE 2013, 8:e69639.
54. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
55. Lee J.H., Choi J.W., Kim Y.S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011, 164:776-784.
56. Lovly C.M., Dahlman K.B., Fohn L.E., et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLOS ONE 2012, 7:e35309.
57. Henary H., Hong D.S., Falchook G.S., et al. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol 2013, 24:2158-2165.
58. Platz A., Egyhazi S., Ringborg U., Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008, 1:395-405.
59. Akslen L.A., Puntervoll H., Bachmann I.M., et al. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 2008, 18:29-35.
60. Si L., Kong Y., Xu X., et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012, 48:94-100.
61. Edlundh-Rose E., Egyházi S., Omholt K., et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006, 16:471-478.
62. Ball N.J., Yohn J.J., Morelli J.G., Norris D.A., Golitz L.E., Hoeffler J.P. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994, 102:285-290.
63. Ellerhorst J.A., Greene V.R., Ekmekcioglu S., et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011, 17:229-235.
64. Griewank K.G., Westekemper H., Murali R., et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 2013, 19:3143-3152.
65. Turri-Zanoni M., Medicina D., Lombardi D., et al. Sinonasal mucosal melanoma: molecular profile and therapeutic implications from a series of 32 cases. Head Neck 2013, 35:1066-1077.
66. Sekine S., Nakanishi Y., Ogawa R., Kouda S., Kanai Y. Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites. Virchows Arch 2009, 454:513-517.
67. Dutton-Regester K., Kakavand H., Aoude L.G., et al. Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell Melanoma Res 2013, 26:852-860.
68. Devitt B., Liu W., Salemi R., et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011, 24:666-672.
69. Nagore E., Hacker E., Martorell-Calatayud A., et al. Prevalence of BRAF and NRAS mutations in fast-growing melanomas. Pigment Cell Melanoma Res 2013, 26:429-431.
70. van Elsas A., Zerp S.F., van der Flier S., et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996, 149:883-893.
71. Demunter A., Stas M., Degreef H., De Wolf-Peeters C., van den Oord J.J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001, 117:1483-1489.
72. Treatment of early-stage breast cancer. JAMA 1991, 265:391-395.
73. Omholt K., Platz A., Kanter L., Ringborg U., Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003, 9:6483-6488.
74. Ugurel S., Thirumaran R.K., Bloethner S., et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2007, 2:e236.
75. Birkeland E., Busch C., Berge E.O., et al. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clin Exp Metastasis 2013, 30:867-876.
76. Demunter A., Ahmadian M.R., Libbrecht L., et al. A novel Nras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res 2001, 61:4916-4922.
77. Houben R., Becker J.C., Kappel A., et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004, 3:6.
78. Jakob J.A., Bassett R.L., Ng C.S., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
79. Omholt K., Karsberg S., Platz A., Kanter L., Ringborg U., Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002, 8:3468-3474.
80. Bucheit A.D., Syklawer E., Jakob J.A., et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 2013 Nov 1, 119:3821-3829.
81. Mann G.J., Pupo G.M., Campain A.E., et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 2013, 133:509-517.
82. Akslen L.A., Angelini S., Straume O., et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 2005, 125:312-317.
83. Ekedahl H., Cirenajwis H., Harbst K., et al. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol 2013, 169:1049-1055.
84. Banerji U., Affolter A., Judson I., Marais R., Workman P. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 2008, 7:737-739.
85. Joseph R.W., Sullivan R.J., Harrell R., et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 2012, 35:66-72.
86. Patel S.P., Lazar A.J., Papadopoulos N.E., et al. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 2013, 119:799-805.
87. Solit D.B., Garraway L.A., Pratilas C.A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
88. Ascierto P.A., Schadendorf D., Berking C., et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256.
89. Winski S., Anderson D., Bouhana K., et al. MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations. Proceedings of the 22nd EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics 2010.
90. Yeh T.C., Marsh V., Bernat B.A., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007, 13:1576-1583.
91. Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
92. Dahlman K.B., Xia J., Hutchinson K., et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012, 2:791-797.
93. Posch C., Moslehi H., Feeney L., et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A 2013, 110:4015-4020.
94. Johnson D.B., Lovly C.M., Flavin M., et al. NRAS mutation: a potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). J Clin Oncol 2013, 31(Supppl.). [abstr 9019].
95. Nazarian R., Shi H., Wang Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
96. Trunzer K., Pavlick A.C., Schuchter L., et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013, 31:1767-1774.
97. McArthur G., Ribas A., Chapman P.B., et al. Molecular analyses from a phase I trial of vemu-rafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation positive metastatic melanoma patients (pts). J Clin Oncol 2011, 29(Suppl.). [abstr 8502].
98. Poulikakos P.I., Persaud Y., Janakiraman M., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
99. Wagle N., Van Allen E.M., Treacy D.J., et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014, 4:61-68.
100. Van Allen E.M., Wagle N., Sucker A., et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014, 4:94-109.
101. Rizos H., Menzies A.M., Pupo G.M., et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014, 20:1965-1977.
102. Dumaz N., Hayward R., Martin J., et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006, 66:9483-9491.
103. Su F., Bradley W.D., Wang Q., et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2012, 72:969-978.
104. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.